Sign In
Last checked at 
16 Oct 2014 16:52
Directorate change: Additional Directorship
Oxford, UK - 16 October 2014: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Group") a leading gene and cell therapy company, announces that in accordance with Listing Rule 9.6.14R, it has been notified that Martin Diggle, a non-executive director, has been appointed as non-executive director of Proteome Sciences plc, with immediate effect.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Jessica Hodgson/Matthew Neal Consilium Strategic Communications |
Tel: +44 (0)20 3709 5700 |
|
|
Notes for editors
About Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Group's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad range of partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
Follow the stocks
